DNA methylation as a clinical biomarker in prostate cancer: diagnostic, prognostic, and therapeutic perspectives
Boletín del Colegio Mexicano de Urología · 06.08.2026 · 40 (2)
DOI: 10.24875/bcmu.25000019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Boletín del Colegio Mexicano de Urología, online erschienen am 06.08.2026. Verfasst von José M. Moreno-Ortíz und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Moreno-Ortíz, J. M., Flores-Islas, A. K., Rico-Fuentes, C., Beltrán-Ontiveros, S. A., Sierra-Díaz, E., Pereira-Suárez, A. L., & Ramírez-de-Arellano, J. A. (2026). DNA methylation as a clinical biomarker in prostate cancer: diagnostic, prognostic, and therapeutic perspectives. Boletín del Colegio Mexicano de Urología, 40(2). https://doi.org/10.24875/bcmu.25000019
Vancouver
Moreno-Ortíz JM, Flores-Islas AK, Rico-Fuentes C, Beltrán-Ontiveros SA, Sierra-Díaz E, Pereira-Suárez AL, et al. DNA methylation as a clinical biomarker in prostate cancer: diagnostic, prognostic, and therapeutic perspectives. Boletín del Colegio Mexicano de Urología. 2026;40(2). doi:10.24875/bcmu.25000019
BibTeX
@article{MorenoOrtz2026,
author = {Moreno-Ortíz, José M. and Flores-Islas, Ana K. and Rico-Fuentes, Cecilia and Beltrán-Ontiveros, Saul A. and Sierra-Díaz, Erick and Pereira-Suárez, Ana L. and Ramírez-de-Arellano, Jorge A.},
title = {DNA methylation as a clinical biomarker in prostate cancer: diagnostic, prognostic, and therapeutic perspectives},
journal = {Boletín del Colegio Mexicano de Urología},
year = {2026},
volume = {40},
number = {2},
doi = {10.24875/bcmu.25000019}
}
EUVIMED